enGene Holdings Inc. (NASDAQ:ENGNW) Sees Significant Drop in Short Interest

enGene Holdings Inc. (NASDAQ:ENGNW) was the target of a significant drop in short interest in the month of March. As of March 31st, there was short interest totaling 583 shares, a drop of 84.4% from the March 15th total of 3,741 shares. Based on an average trading volume of 1,703 shares, the days-to-cover ratio is presently 0.3 days.

enGene Stock Down 5.0%

Shares of NASDAQ ENGNW traded down $0.12 during trading hours on Friday, reaching $2.28. The stock had a trading volume of 2,400 shares, compared to its average volume of 17,161. The business’s fifty day moving average price is $2.79 and its two-hundred day moving average price is $2.49. enGene has a 52-week low of $0.51 and a 52-week high of $4.20.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.